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The potential benefits of gaining body muscle for cardiovascular disease (CVD) susceptibil-
ity, and how these compare with the potential harms of gaining body fat, are unknown. We
compared associations of early life changes in body lean mass and handgrip strength ver-
sus body fat mass with atherogenic traits measured in young adulthood.
Methods and findings
Data were from 3,227 offspring of the Avon Longitudinal Study of Parents and Children
(39% male; recruited in 1991–1992). Limb lean and total fat mass indices (kg/m2) were mea-
sured using dual-energy X-ray absorptiometry scans performed at age 10, 13, 18, and 25 y
(across clinics occurring from 2001–2003 to 2015–2017). Handgrip strength was measured
at 12 and 25 y, expressed as maximum grip (kg or lb/in2) and relative grip (maximum grip/
weight in kilograms). Linear regression models were used to examine associations of
change in standardised measures of these exposures across different stages of body devel-
opment with 228 cardiometabolic traits measured at age 25 y including blood pressure, fast-
ing insulin, and metabolomics-derived apolipoprotein B lipids. SD-unit gain in limb lean
mass index from 10 to 25 y was positively associated with atherogenic traits including very-
low-density lipoprotein (VLDL) triglycerides. This pattern was limited to lean gain in legs,
whereas lean gain in arms was inversely associated with traits including VLDL triglycerides,
insulin, and glycoprotein acetyls, and was also positively associated with creatinine (a mus-
cle product and positive control). Furthermore, this pattern for arm lean mass index was spe-
cific to SD-unit gains occurring between 13 and 18 y, e.g., −0.13 SD (95% CI −0.22, −0.04)
for VLDL triglycerides. Changes in maximum and relative grip from 12 to 25 y were both
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positively associated with creatinine, but only change in relative grip was also inversely
associated with atherogenic traits, e.g., −0.12 SD (95% CI −0.18, −0.06) for VLDL triglycer-
ides per SD-unit gain. Change in fat mass index from 10 to 25 y was more strongly associ-
ated with atherogenic traits including VLDL triglycerides, at 0.45 SD (95% CI 0.39, 0.52);
these estimates were directionally consistent across sub-periods, with larger effect sizes
with more recent gains. Associations of lean, grip, and fat measures with traits were more
pronounced among males. Study limitations include potential residual confounding of obser-
vational estimates, including by ectopic fat within muscle, and the absence of grip measures
in adolescence for estimates of grip change over sub-periods.
Conclusions
In this study, we found that muscle strengthening, as indicated by grip strength gain, was
weakly associated with lower atherogenic trait levels in young adulthood, at a smaller magni-
tude than unfavourable associations of fat mass gain. Associations of muscle mass gain
with such traits appear to be smaller and limited to gains occurring in adolescence. These
results suggest that body muscle is less robustly associated with markers of CVD suscepti-
bility than body fat and may therefore be a lower-priority intervention target.
Author summary
Why was this study done?
• Higher body fat likely causes heart disease, but fat loss remains difficult to maintain. Evi-
dence is less robust on whether gaining body muscle mass or strength would reduce the
risk of heart disease, and how the size of potential benefit from muscle or strength gain
compares with the expected harm of fat gain.
• Examining naturally occurring changes in lean mass, grip strength, and fat mass across
early stages of life, when ageing-related chronic diseases are rare, should naturally
reduce the potential for confounding by subclinical disease and enable less biased esti-
mates of the effect of each body compartment on markers of heart health.
What did the researchers do and find?
• We used data on approximately 3,000 young people from a British birth cohort study to
examine repeated measures of body fat and lean mass taken from body scanning per-
formed during childhood, adolescence, and young adulthood, as well as repeated mea-
sures of handgrip strength from childhood and young adulthood.
• We examined associations between these exposures and detailed measures taken from
blood samples in young adulthood including apolipoprotein-B-related cholesterol,
which reflects susceptibility to heart disease. This enabled us to compare how strongly
different body compartments relate to heart health and to pinpoint at what stage of
early life (before adulthood) each may be most impactful.
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• We found that gaining lean mass and grip strength were only weakly related to healthier
levels of blood markers in young adulthood, and mainly among males, with only lean
mass gains occurring in adolescence appearing potentially beneficial. Gaining fat mass
was more strongly and consistently related to poorer health in young adulthood, again
particularly among males.
What do these findings mean?
• These findings suggest that greater benefits to heart health may be expected from reduc-
ing body fat than from gaining body muscle. They further suggest that the regular use of
muscle matters more than the volume or intentional building up of muscle for avoiding
heart disease.
• Body muscle is still likely to benefit other functional aspects of health including mobil-
ity, and these benefits should still be relayed to patients and the public.
Introduction
Cardiovascular diseases (CVDs) remain leading causes of early mortality [1]. Multiple lines of
evidence from population and mechanistic studies support higher body fat as a likely cause of
such diseases, including coronary heart disease (CHD) [2–5]. These harms of body fatness are
thought to be driven largely by its effects on cardiometabolic intermediates including higher
blood pressure, apolipoprotein-B-containing lipoproteins, and glucose [6,7]. Population
reductions in body fat remain difficult to achieve, however [8]. This reality motivates the direct
targeting of intermediate traits and of other metabolically active, and potentially modifiable,
body tissues.
Body muscle is metabolically active and its contraction is expected to be anti-inflammatory
and anti-hyperglycaemic [9]. Higher total lean mass has shown adverse cardiometabolic pro-
files [10,11] however, possibly reflecting residual confounding by fat in abdominal regions [4].
Lean mass held within limbs may better isolate skeletal muscle as these compartments corre-
late most highly with muscle volume measured by magnetic resonance imaging [12,13]. Bene-
fits of muscle may also be reflected in strength, which can be measured directly for isolated
arm muscles using handgrip tests; grip strength correlates well (>0.7) with objectively mea-
sured strength in other muscle groups such as hips and is thus a useful and widely used proxy
for overall muscular strength in larger scale studies [14–16]. Prospective observational esti-
mates suggest that higher limb lean mass and stronger grip are both associated with lower
CHD risk independent of body mass index (BMI) [14,17,18], and factorial Mendelian rando-
misation (MR) estimates suggest that the risk ratio for CVD onset is comparable among adults
with high grip strength and high BMI (1.04; 95% CI 0.98, 1.11) and among adults with low
grip strength and high BMI (1.03; 95% CI 0.97, 1.10), compared with adults with high grip
strength and low BMI (P value for interaction = 0.50) [19]. Such factorial MR estimates for
limb lean mass, whether based on bioimpedance or more precise dual-energy X-ray absorpti-
ometry (DXA) scans, are not yet available.
The likely causality between body muscle and CVD susceptibility can be interrogated by
examining the association of body muscle with intermediate traits that have triangulated
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evidence of causality for CVD in samples that have reduced potential for confounding. Higher
limb lean mass and stronger grip are both associated with lower glycaemia, apolipoprotein B
lipids, blood pressure, and inflammation [20–23]. These associations for grip appear stronger
when expressed as a function of, rather than adjusting for, weight or BMI [20–25]. Notably,
estimates for limb lean mass and grip are based largely on middle- to older-age adults, which
limits causal inference given the high potential for confounding by subclinical disease (reverse
causation). The few studies of children or young adults suggest weak associations of stronger
grip with total cholesterol, glucose, and blood pressure [26–29], and potentially positive associ-
ations of higher limb lean mass with atherogenic lipids, glycaemia, and blood pressure [11].
Measuring muscle and strength earlier in life, when subclinical diseases are rare, should enable
less biased estimates of cardiometabolic effects.
Growing evidence suggests that associations between body fat mass and atherogenic traits
differ importantly by sex. Higher fat mass, whether measured using BMI, waist circumference,
or DXA fat mass, appears to be more strongly positively associated among males with CVD-
relevant traits including metabolomics-derived glucose, apolipoprotein B lipids, and inflam-
matory glycoprotein acetyls (GlycA) [7,30]; these sex differences in turn vary by stage of body
development, with associations appearing more adverse among males in childhood, adoles-
cence, and young adulthood, but similar or more adverse among females in middle adulthood
[30]. Such differences do not simply reflect differences in total fat volume since males tend to
carry less total fat than females throughout life [30,31]; these differences instead suggest an
important role of abdominal and ectopic fat storage, which is often higher among males [4,31],
in underpinning the effects of total fat [10]. Males tend to have higher lean mass and stronger
grip than females [14,32], but whether important sex differences exist in the associations of
muscle mass or strength with atherogenic traits is unknown. Sex differences in the potential
benefits of muscle have also not been previously examined in relation to detailed atherogenic
traits measured from targeted metabolomics [33]. Muscle tissue is thought to be more modifi-
able after childhood [34], and thus greater benefits from a higher contractile capacity may be
expected from adolescence onwards, but the common lack of repeated measures of body mus-
cle at different life stages has prevented examination of the potential modifying role of growth
and development in the associations of muscle change with atherogenic traits [35].
We aimed in this study to estimate the effects of gaining body muscle on markers of CVD
susceptibility using repeated measures of DXA limb lean mass and grip strength across early
life in relation to blood pressure and metabolomics-derived atherogenic traits in young adult-
hood. We examined associations of change in limb lean mass and grip from childhood to
young adulthood with atherogenic traits, and whether associations differ by stage of body
development and by sex. We examined associations of change in DXA fat mass index with
traits in the same manner, to directly compare the magnitude of potential benefits of gaining
muscle with the potential harms of gaining fat.
Methods
Study population
Data were from Generation 1 of the Avon Longitudinal Study of Parents and Children
(ALSPAC), a population-based birth cohort study in which 15,454 pregnant women (Genera-
tion 0) with an expected delivery date between 1 April 1991 and 31 December 1992 were
recruited from the former Avon County of southwest England [36]. Since then, 14,901 Genera-
tion 1 individuals alive at 1 y have been followed repeatedly with questionnaire- and clinic-
based assessments [37–39], including an additional 913 Generation 1 individuals enrolled over
the course of the study [40]. Written informed consent was provided, and ethical approval was
PLOS MEDICINE Body muscle and CVD susceptibility
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obtained from the ALSPAC Ethics and Law Committee and the local research ethics commit-
tee. Consent for biological samples was collected in accordance with the UK Human Tissue
Act 2004. Written informed consent for the use of data collected via questionnaires and clinics
was obtained from participants following recommendations of the ALSPAC Ethics and Law
Committee at the time. The study website contains details of all available data through a fully
searchable data dictionary and variable search tool (http://www.bristol.ac.uk/alspac/
researchers/our-data/).
Our study aims, objectives, and analytical intentions were summarised in March 2019 prior
to data handling for the purposes of an ALSPAC data application (S1 Study Plan). This study
was initially motivated by metabolomics work on type 2 diabetes susceptibility [41] and was
expanded to investigate CVD susceptibility more broadly. Examinations of sex differences
were motivated by more recent work on body fatness [30] and prior peer review recommenda-
tions. This study is reported as per the Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) guidelines (S1 STROBE Checklist).
We conducted main analyses on unrestricted samples of participants (with N varying
between traits and across occasions) to enable use of all measured data. Of the 14,901 surviving
Generation 1 ALSPAC participants who were eligible for future clinic assessments, 6,119 par-
ticipants had data on covariates used for model adjustments plus�1 of any of the following:
DXA measures (lean or fat mass) or grip strength at age 25 y; change in DXA measures across
the total observation period (10 to 25 y), across childhood (10 to 13 y), across adolescence (13
to 18 y), or across young adulthood (18 to 25 y); or change in grip strength across the total
observation period (12 to 25 y). Of those 6,119 participants with any exposure measure, 3,227
participants had data on�1 cardiometabolic trait at age 25 y and were thus considered eligible
for inclusion in at least 1 of the present set of analyses (Fig 1).
Assessing body muscle mass and strength
When aged approximately 10, 12, 13, 18, and 25 y, participants underwent body scanning using a
DXA Lunar Prodigy narrow fan beam densitometer, from which total and regional lean mass (in
kilograms, excluding fat and bone) was estimated. Scans were screened for anomalies, motion,
and material artefacts, and realigned when necessary [42]. Limb lean mass was calculated by sum-
ming lean mass in arms and legs (trunk excluded). On each occasion, height was measured in
light clothing without shoes to the nearest 0.1 cm using a Harpenden stadiometer. Limb lean
mass index was calculated using squared height (kg/m2). Separate lean mass indices for arms and
legs were also calculated. Fat mass index was calculated based on total body fat mass (kg/m2).
Participants underwent handgrip strength testing on 2 occasions: when aged approximately
12 y using a Jamar hydraulic dynamometer and when aged approximately 25 y using a Baseline
pneumatic squeeze bulb dynamometer. The latter device records grip more dynamically, with
units scaled to hand size; previous studies of younger and older adults suggest that measure-
ments from squeeze bulb dynamometers and Jamar hydraulic devices are highly correlated (r
> 0.8) and similarly detect sex differences in grip strength [43,44]. On each occasion, partici-
pants sat in a chair with arms and back supported and were asked to rest their forearms on the
arms of the chair, with their wrist just over the end of the chair arm (thumb facing upwards,
with wrist in a neutral position). Participants were asked to squeeze the device as tightly and
for as long as possible, 3 times in succession using their dominant (writing) hand, to record
maximum isometric strength (in kilograms of force at 12 y and in pounds per square inch of
force at 25 y). Maximum grip strength was estimated as the mean of 3 measures. Grip strength
as a function of body weight, here termed ‘relative grip’, was calculated as maximum grip
divided by body weight in kilograms. We scaled for weight rather than fat mass index or BMI
PLOS MEDICINE Body muscle and CVD susceptibility
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when deriving relative grip following peer review; this approach was considered preferable
because it (1) accounts for overall body size rather than adiposity specifically, (2) reduces bias
from an induced negative correlation between relative grip strength and adiposity, (3) enables
consistent multivariable adjustment for fat mass index as a confounder across muscle mea-
sures, and (4) enables comparable estimates of effect with MR analyses, given that genome-
wide association studies have scaled for weight rather than BMI [45].
Assessing cardiometabolic traits
When the participants were aged approximately 25 y, systolic blood pressure (SBP) and dia-
stolic blood pressure (DBP) were examined twice in succession while the individual was seated
with the arm supported, using an appropriately sized cuff and a DINAMAP 9301 device. Mean
levels of each were used to represent resting SBP and DBP. Fasting blood samples were drawn,
from which insulin (mu/l) and C-reactive protein (CRP) (mg/l) were quantified using routine
clinical chemistry. Proton nuclear magnetic resonance (NMR) spectroscopy from targeted
metabolomics [33] was also performed to quantify 145 concentrations (mostly mmol/l) and 79
ratios describing traits including cholesterol and triglyceride content of lipoprotein subclasses,
apolipoprotein B, glucose, branched chain amino acids (BCAAs), creatinine (a muscle product
and positive control), and inflammatory GlycA.
Assessing confounders
The measured confounders included sex, ethnicity (white versus non-white), age at the time of
exposure (lean mass, grip, fat mass) assessment, and highest level of education attained by the
participant’s mother as reported shortly after delivery (certificate of secondary education,
vocational, O-level, A-level, or degree, using English standards) to indicate socioeconomic
position at birth. Smoking at age 18 y and 25 y was recorded via questionnaire and grouped as
never smoked an entire cigarette, smokes less than weekly, or smokes weekly. Alcohol con-
sumption at 18 y and 25 y was recorded and grouped as never/monthly/less than monthly, 2–4
Fig 1. Selection of Avon Longitudinal Study of Parents and Children Generation 1 participants eligible for
inclusion in�1 analysis. DXA, dual-energy X-ray absorptiometry.
https://doi.org/10.1371/journal.pmed.1003751.g001
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times/month, or�2 times/week. Puberty timing was estimated as age at peak height velocity
based on SuperImposition by Translation and Rotation (SITAR) modelling of heights from 5 y
to 20 y (detailed previously [46]).
Analyses
Pearson correlation coefficients were examined between changes in lean and fat mass indices
based on age 10 and 25 y measures, and between changes in grip and lean and fat mass indices
based on age 12 and 25 y measures. Correlations were also examined between changes in lean
and fat mass indices across sub-periods of childhood (10 to 13 y), adolescence (13 to 18 y), and
young adulthood (18 to 25 y).
Exposures and outcomes were analysed in standardised z-score units to allow comparability
of effect sizes given dissimilar variances between traits and across occasions (this also improved
comparability between handgrip strength measures, given the different units across occasions).
Because exposure distributions differed substantially by sex (S1–S5 Figs), as did exposure
change distributions (S6–S10 Figs), exposures were z-scored separately within each sex. We
then examined associations of change in lean mass indices (total limb, arm, and leg) based on
difference scores (standardised index at 25 y minus standardised index at 10 y) with cardiome-
tabolic traits at 25 y using linear regression models with robust standard errors. Models adjusted
for age, sex, ethnicity, maternal education, the 10-y value of the index being assessed, change in
the other lean mass index (other limb compartment), and change in fat mass index. We exam-
ined whether association patterns differed by stage of body development by repeating analyses
based on change in lean mass indices from 10 to 13 y (childhood), 13 to 18 y (adolescence), and
18 to 25 y (young adulthood), in relation to traits at 25 y. Models of change in adolescence were
additionally adjusted for age at peak height velocity, while models of change in young adulthood
were additionally adjusted for this plus smoking and alcohol at 18 y. Associations of change in
grip measures from 12 to 25 y with traits at 25 y were examined with adjustment for basic
demographic factors, grip strength at 12 y, and change in fat mass index.
We examined associations of change in fat mass index from 10 to 25 y, and over sub-peri-
ods, with traits at 25 y, using the same model adjustment strategies as for limb lean mass index
but adjusting for limb lean (instead of fat) mass index. Lastly, following peer review, we exam-
ined cross-sectional associations of lean mass indices, grip strength, and fat mass index with
cardiometabolic traits, all measured at 25 y, to compare the association profile of changes in
exposures to that of current levels of exposure. These models were adjusted for the same covar-
iates as in models with exposure change measured starting from 18 y, but with smoking, alco-
hol, and lean/fat mass indices now measured at 25 y. We examined whether associations differ
substantially by sex by repeating all analyses among males and females separately.
Since main analyses were conducted on unrestricted samples of participants (with N vary-
ing between traits and across occasions), we repeated models using 770 participants with data
on every DXA and grip measure at every time point, every cardiometabolic trait, and every
covariate (complete case), to examine whether results are sensitive to changing sample size.
As recommended for aims of estimation [47,48], we present exact P values and base our
interpretations of results on effect size and precision. Analyses were done using Stata 15.1 (Sta-
taCorp, College Station, Texas, US).
Results
Sample characteristics
In total, 3,227 participants contributed to analyses (39% male) (Table 1; Fig 1). Mean (SD) age
at peak height velocity was 12.4 y (1.2 y) overall (range: 9.1 y to 17.4 y). Based on this indicator,
PLOS MEDICINE Body muscle and CVD susceptibility
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0.4% of participants entered puberty by 10 y (when lean/fat mass was first assessed), 29.9% did
by 12 y (when grip was first assessed), and all did by 25 y. Changes in lean mass indices were
generally positive but smaller than positive changes in fat mass index; all were highly variable
Table 1. Characteristics of 3,227 Avon Longitudinal Study of Parents and Children Generation 1 offspring eligible for analyses.
Characteristics Overall (N = 3,227) Males (N = 1,257) Females (N = 1,970)
N Percent (N) or mean (SD) N Percent (N) or mean (SD) N Percent (N) or mean (SD)
Non-white ethnicity 3,227 3.9% (126) 1,257 3.7% (47) 1,970 4.0% (79)
Maternal education is degree 3,227 21.0% (676) 1,257 22.4% (282) 1,970 20.0% (394)
Age (y) at peak height velocity 2,924 12.4 (1.2) 1,155 13.5 (0.9) 1,769 11.8 (0.8)
Smoking at 25 y 3,191 1,240 1,951
Never 36.1% (1,153) 35.4% (439) 36.6% (714)
Less than weekly 58.3% (1,859) 57.6% (714) 58.7% (1,145)
Every week 5.6% (179) 7.0% (87) 4.7% (92)
Alcohol consumption at 25 y 3,123 1,209 1,914
Never/monthly/less than monthly 24.0% (748) 17.6% (213) 28.0% (535)
2 to 4 times per month 38.5% (1,202) 36.6% (443) 39.7% (759)
2 or more times per week 37.6% (1,173) 45.7% (553) 32.4% (620)
Total limb lean mass index (kg/m2) at 25 y 3,119 7.2 (1.3) 1,222 8.2 (1.1) 1,897 6.5 (0.9)
Arm lean mass index (kg/m2) at 25 y 3,119 1.7 (0.5) 1,222 2.2 (0.4) 1,897 1.5 (0.2)
Leg lean mass index (kg/m2) at 25 y 3,119 5.4 (0.9) 1,222 6.0 (0.8) 1,897 5.1 (0.7)
Maximum grip strength (lb/in2) at 25 y 1,964 14.1 (3.9) 771 17.4 (3.7) 1,193 12.1 (2.3)
Relative grip strength (lb/in2/kg) at 25 y 1,951 0.2 (0.1) 768 0.2 (0.1) 1,183 0.2 (0.04)
Total fat mass index (kg/m2) at 25 y 3,119 7.9 (3.7) 1,222 6.3 (3.0) 1,897 9.0 (3.8)
Changes from childhood to young adulthood, 10 to 25 y
Total limb lean mass index (kg/m2) 2,808 1.8 (1.0) 1,102 2.6 (0.9) 1,706 1.3 (0.7)
Arm lean mass index (kg/m2) 2,808 0.6 (0.4) 1,102 0.9 (0.3) 1,706 0.3 (0.2)
Leg lean mass index (kg/m2) 2,808 1.2 (0.7) 1,102 1.6 (0.7) 1,706 1.0 (0.6)
Maximum grip strength (SD)� 1,739 −0.001 (1.1) 681 −0.004 (1.1) 1,058 0.001 (1.1)
Relative grip strength (SD)� 1,727 −0.04 (1.0) 678 −0.01 (1.0) 1,049 −0.1 (1.0)
Total fat mass index (kg/m2) 2,808 3.6 (3.0) 1,102 2.6 (2.4) 1,706 4.2 (3.1)
Changes in childhood, 10 to 13 y
Total limb lean mass index (kg/m2) 2,565 1.0 (0.6) 1,017 1.3 (0.6) 1,548 0.7 (0.4)
Arm lean mass index (kg/m2) 2,565 0.3 (0.2) 1,017 0.4 (0.2) 1,548 0.2 (0.1)
Leg lean mass index (kg/m2) 2,565 0.7 (0.4) 1,017 1.0 (0.4) 1,548 0.5 (0.3)
Total fat mass index (kg/m2) 2,565 0.9 (1.7) 1,017 0.3 (1.6) 1,548 1.3 (1.6)
Changes in adolescence, 13 to 18 y
Total limb lean mass index (kg/m2) 2,404 0.3 (0.6) 934 0.8 (0.7) 1,470 −0.02 (0.4)
Arm lean mass index (kg/m2) 2,404 0.2 (0.2) 934 0.4 (0.2) 1,470 0.1 (0.1)
Leg lean mass index (kg/m2) 2,404 0.1 (0.5) 934 0.3 (0.5) 1,470 −0.1 (0.3)
Total fat mass index (kg/m2) 2,404 1.1 (2.0) 934 0.3 (1.9) 1,470 1.6 (1.9)
Changes in young adulthood, 18 to 25 y
Total limb lean mass index (kg/m2) 2,543 0.5 (0.7) 983 0.4 (0.8) 1,560 0.6 (0.7)
Arm lean mass index (kg/m2) 2,543 0.1 (0.2) 983 0.1 (0.3) 1,560 0.03 (0.2)
Leg lean mass index (kg/m2) 2,543 0.5 (0.6) 983 0.3 (0.6) 1,560 0.6 (0.6)
Total fat mass index (kg/m2) 2,543 1.6 (2.4) 983 2.2 (2.1) 1,560 1.3 (2.5)
Described are those with data on change in at least 1 lean, grip, or fat measure across any occasion and covariates used for those models, and at least 1 cardiometabolic
trait at 25 y.
�Change is from age 12 y to 25 y and is based on difference in SD units, given different original measurement units between occasions.
https://doi.org/10.1371/journal.pmed.1003751.t001
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(Table 1). Overall, males experienced more positive change in lean mass indices and grip,
whereas females experienced more positive change in fat mass index; sex differences appeared
largest before young adulthood (Table 1; S6–S10 Figs).
Ineligible participants were more likely than eligible participants to be male (54.5%) and to
have lower maternal education; they also showed similar smoking patterns but lower levels of
weekly drinking at 25 y (S1 Table). Changes in lean and fat mass indices were similar.
Correlations among lean mass indices, grip strength, and fat mass index
Change in limb lean mass index between ages 12 and 25 y was positively correlated with
change in maximum grip (r = 0.33) but negatively correlated with change in relative grip (r =
−0.12) over this same period. Change in limb lean mass index was positively correlated with
change in fat mass index over this same period (r = 0.39), as well as between the ages 10 and 25
y (r = 0.47). Change in limb lean mass index was more positively correlated with change in leg
lean mass index than change in arm lean mass index, based on either time period (S2 and S3
Tables). Based on changes occurring between the ages 12 and 25 y, fat mass index change was
uncorrelated with maximum grip change (r = 0.03) but negatively correlated with relative grip
change (r = −0.44). Considering different sub-periods, change in fat mass index was more pos-
itively correlated with change in arm lean mass index than change in leg lean mass index over
childhood and adolescence (S4 and S5 Tables), but was more positively correlated with change
in leg than arm lean mass index in young adulthood (S6 Table). A similar correlation pattern
was seen cross-sectionally based on measures taken at age 25 y (S7 Table).
Associations of changes in limb lean mass indices with cardiometabolic traits
Evidence was strong for associations of change in limb lean mass index from 10 to 25 y (per
SD-unit gain) with higher creatinine and most atherogenic traits; these were of modest magni-
tude and mostly in directions assumed to reflect poorer health, e.g., 0.17 SD (95% CI 0.10,
0.24) higher very-low-density lipoprotein (VLDL) triglycerides (Fig 2; S8 Table). When exam-
ining gains in arm and leg lean mass indices separately, only gain in arm lean mass was posi-
tively associated with creatinine. The adverse pattern of associations seen across traits with
limb lean mass index gain appeared limited to gain in leg lean mass, whereas gain in arm lean
mass was associated with traits including lower VLDL triglycerides (−0.09 SD; 95% CI −0.15,
−0.02), insulin, GlycA, and DBP, but higher SBP. This pattern for creatinine and atherogenic
traits was more pronounced among males (S9 and S10 Tables).
Change in limb lean mass index from 10 to 13 y was generally associated with higher ath-
erogenic lipids at 25 y including low-density lipoprotein cholesterol and VLDL triglycerides, at
0.19 SD (95% CI 0.13, 0.26); positive associations were apparent with apolipoprotein B, insulin,
GlycA, SBP, and DBP (Figs 3 and 4; S11 Table). Gain in both limb compartments was posi-
tively associated with creatinine, and adverse trait profiles seen with childhood gain in limb
lean mass index were reflected in arms as well as legs. Effect sizes appeared larger among males
(S12 and S13 Tables).
Change in limb lean mass index from 13 to 18 y was generally unassociated with creatinine
and atherogenic traits at 25 y, apart from weak associations with higher SBP and DBP (Figs 3
and 4; S14 Table). In contrast, gain in arm lean mass index was positively associated with creat-
inine and inversely associated with atherogenic traits including VLDL triglycerides (−0.13 SD;
95% CI −0.22, −0.04), apolipoprotein B, insulin, GlycA, and DBP, but positively associated
with SBP. Associations were again stronger among males (S15 and S16 Tables).
Change in limb lean mass index from 18 to 25 y was associated with higher creatinine and
atherogenic traits at 25 y including higher VLDL triglycerides (Figs 3 and 4; S17 Table). The
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positive association with creatinine was again exclusive to arms, and gain in arm lean mass
was generally unassociated with atherogenic traits except for a positive association with DBP.
Such null associations were seen among males and females, despite a strong positive associa-
tion of gain in arm lean mass with creatinine among males (S18 and S19 Tables).
Associations of change in grip strength with cardiometabolic traits
Change in maximum grip from 12 to 25 y (per SD-unit gain) was positively associated with
creatinine, but associations were largely null with atherogenic traits, including VLDL triglycer-
ides (−0.01 SD; 95% CI −0.07, 0.04) (Fig 5; S20 Table), among males and females (S21 and S22
Tables). In contrast, change in relative grip over the same period was positively associated with
creatinine and moderately inversely associated with atherogenic traits, e.g., VLDL triglycer-
ides, at −0.12 SD (95% CI −0.18, −0.06), with similar magnitudes for apolipoprotein B, insulin,
GlycA, SBP, and DBP. These associations appeared strongest among females.
Associations of change in fat mass index with cardiometabolic traits
Change in fat mass index (per SD-unit gain) was inversely associated with creatinine and
strongly positively associated with atherogenic traits including VLDL triglycerides (0.45 SD;
95% CI 0.39, 0.52), apolipoprotein B, insulin, GlycA, SBP, and DBP (Fig 6; S23 Table). When
examining gains over sub-periods in relation to traits at 25 y, estimates were directionally con-
sistent across occasions, with a tendency for larger effect sizes with more recent gains. For
Fig 2. Associations of change in limb lean mass indices from age 10 y to 25 y with cardiometabolic traits at 25 y among Avon Longitudinal Study of Parents and
Children Generation 1 individuals. Estimates are beta coefficients and 95% CIs representing SD-unit differences in cardiometabolic traits at 25 y per SD-unit gain in
lean mass index from 10 y to 25 y (based on standardised index at 25 y minus standardised index at 10 y). Models adjusted for age, sex, ethnicity, maternal education,
lean mass index at 10 y, change in the other lean mass index, and change in total fat mass index (N range: 2,121 to 2,804). Limb lean mass index defined as sum of lean
mass in arms and legs (kg) divided by squared height (m2). Apo, apolipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; IDL, intermediate-
density lipoprotein; VLDL, very-low-density lipoprotein.
https://doi.org/10.1371/journal.pmed.1003751.g002
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example, point estimates for associations of fat gain in childhood, adolescence, and young
adulthood with VLDL triglycerides at 25 y were 0.10 SD, 0.34 SD, and 0.48 SD, respectively.
Associations were more pronounced among males, at about double the magnitude of effect
size, versus females (S24 and S25 Tables).
Cross-sectional associations of lean mass indices, grip strength, and fat
mass index with cardiometabolic traits in young adulthood
Evidence was weaker for cross-sectional associations of higher limb lean mass (per SD) with
atherogenic lipid, glycaemic, and inflammatory traits, e.g., −0.04 SD (95% CI −0.10, 0.01) for
apolipoprotein B (S26 Table). Also, in contrast to estimates based on change in exposure, esti-
mates appeared more favourable for each SD higher leg lean mass index, e.g., apolipoprotein B
was −0.10 SD (95% CI −0.18, −0.01) lower but 0.05 SD (95% CI −0.02, 0.11) higher for leg and
arm lean mass indices, respectively. Leg lean mass index was more positively associated with
creatinine than was arm lean mass index (point estimates were 0.21 SD and 0.13 SD, respec-
tively). These associations were more pronounced among females than males despite similarly
positive associations of lean mass indices with creatinine between the sexes (S27 and S28
Tables).
Evidence was substantially weaker or null for cross-sectional associations of both grip
strength measures (per SD) with atherogenic lipid, glycaemic, and inflammatory traits, e.g.,
0.01 SD (95% CI −0.05, 0.07) for apolipoprotein B with stronger relative grip (S29 Table).
Associations were more evident among males, with estimates appearing positive in relation to
VLDL lipids, e.g., 0.10 SD (95% CI −0.02, 0.22) for total lipids in very large VLDL (S30 and
Fig 3. Associations of change in limb lean mass indices across different life stages with lipid traits at 25 y among Avon Longitudinal Study of Parents and
Children Generation 1 individuals. Estimates are beta coefficients and 95% CIs representing SD-unit differences in cardiometabolic traits at 25 y per SD-unit change in
lean mass index (based on standardised index at time 2 minus standardised index at time 1). Childhood models are based on change in lean mass index from 10 y to 13 y
and are adjusted for age, sex, ethnicity, maternal education, lean mass index at 10 y, change in the other lean mass index, and change in total fat mass index (N range:
1,926 to 2,557). Adolescence models are based on change in lean mass index from 13 y to 18 y and are adjusted for age, sex, ethnicity, maternal education, puberty
timing, change in the other lean mass index, and change in total fat mass index (N range: 1,747 to 2,344). Young adulthood models are based on change in lean mass
index from 18 y to 25 y and are adjusted for age, sex, ethnicity, maternal education, puberty timing, smoking, alcohol, change in the other lean mass index, and change
in total fat mass index (N range: 1,532 to 2,036). Limb lean mass index defined as sum of lean mass in arms and legs (kg) divided by squared height (m2). LDL, low-
density lipoprotein; HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; VLDL, very-low-density lipoprotein.
https://doi.org/10.1371/journal.pmed.1003751.g003
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S31 Tables). Maximum grip was more positively associated with creatinine than was relative
grip, in both sexes.
In contrast, the direction and magnitude of cross-sectional associations of higher fat mass
index with atherogenic traits were highly comparable to those from previous models of change
in exposure (S32 Table). For example, higher fat mass index (per SD) was associated with 0.42
SD (95% CI 0.36, 0.48) higher triglycerides in VLDL, 0.47 SD (95% CI 0.41, 0.53) higher insu-
lin, and 0.53 SD (95% CI 0.48, 0.58) higher GlycA. Associations for most traits were compara-
ble between the sexes, except for non-high-density lipoprotein (non-HDL) lipids, which were
more positive among males (S32 Table).
Estimates based on complete case analyses were comparable to those of the main analyses
in terms of direction and magnitude, with expectedly lower precision given smaller Ns (S8–
S32 Tables).
Discussion
This study aimed to estimate the potential benefits of gaining body muscle for markers of
CVD susceptibility in young adulthood, and how these compare with the potential harms of
gaining body fat. We integrated repeated measures of DXA limb lean and fat mass indices and
grip strength starting in childhood with metabolomic measures of atherogenic traits taken in
young adulthood. Our results suggest that muscle strengthening, as indicated by grip strength
gain, is weakly associated with lower atherogenic trait levels, particularly among males. Associ-
ations of gain in muscle mass with traits were smaller in magnitude and limited to gains occur-
ring in adolescence. Gaining body fat was more consistently associated with the same traits, in
unfavourable directions and at larger magnitudes than seen for muscle mass or strength, again
Fig 4. Associations of change in limb lean mass indices across different life stages with lipid, pre-glycaemic, inflammatory, and blood pressure traits at 25 y
among Avon Longitudinal Study of Parents and Children Generation 1 individuals. Estimates are beta coefficients and 95% CIs representing SD-unit differences in
cardiometabolic traits at 25 y per SD-unit change in lean mass index (based on standardised index at time 2 minus standardised index at time 1). Childhood models are
based on change in lean mass index from 10 y to 13 y and are adjusted for age, sex, ethnicity, maternal education, lean mass index at 10 y, change in the other lean mass
index, and change in total fat mass index (N range: 1,926 to 2,557). Adolescence models are based on change in lean mass index from 13 y to 18 y and are adjusted for
age, sex, ethnicity, maternal education, puberty timing, change in the other lean mass index, and change in total fat mass index (N range: 1,747 to 2,344). Young
adulthood models are based on change in lean mass index from 18 y to 25 y and are adjusted for age, sex, ethnicity, maternal education, puberty timing, smoking,
alcohol, change in the other lean mass index, and change in total fat mass index (N range: 1,532 to 2,036). Limb lean mass index defined as sum of lean mass in arms and
legs (kg) divided by squared height (m2). Apo, apolipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; VLDL, very-low-density lipoprotein.
https://doi.org/10.1371/journal.pmed.1003751.g004
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particularly among males. Altogether, the results suggest that body muscle is less robustly asso-
ciated with markers of CVD susceptibility than body fat and may therefore be a lower-priority
intervention target.
The cardiometabolic traits considered here include several lipoproteins that previous
ALSPAC analyses suggested are positively associated with a genetic risk score for adult CHD;
higher levels of these traits are thus taken to reflect greater liability for developing CHD [49].
These liability traits/features, already apparent in childhood, include cholesterol and triglycer-
ides within non-HDL particles that contain apolipoprotein B, which enables lipid-mediated
atherosclerosis [50]. In the present study, evidence was very weak for associations of change in
limb lean mass index with these lipid types. Gain in limb lean mass in adolescence was more
strongly associated with lower apolipoprotein B lipids; this association appeared to be further
limited to adolescent gains occurring within arms and was more pronounced among males,
indicating that favourable associations of muscle gain may be sensitive to stage of body devel-
opment, limb compartment, and sex. However, the apparent specificity for arms most likely
reflects residual confounding of leg lean mass by ectopic fat; this is supported by stronger asso-
ciations of arm lean mass change (versus leg) with higher creatinine (a muscle product/positive
control), and by weaker correlations of arm lean mass change (versus leg) with fat mass
change.
Results based on cross-sectional models of lean mass indices in relation to atherogenic traits
were not consistent with results based on prospective models. When considering measures
Fig 5. Associations of change in grip strength from age 12 y to 25 y with cardiometabolic traits at 25 y among Avon Longitudinal Study of Parents and Children
Generation 1 individuals. Estimates are beta coefficients and 95% CIs representing SD-unit differences in cardiometabolic traits at 25 y per SD-unit change in grip
strength (based on standardised grip at 25 y minus standardised grip at 12 y). Models are adjusted for age, sex, ethnicity, maternal education, grip strength at 12 y, and
change in total fat mass index (except for relative grip models) (N range: 1,246 to 1,678). Maximum grip is based on maximum recorded grip strength of dominant hand
(mean of 3 measures, in kilograms). Relative grip is based on maximum grip strength divided by weight. Apo, apolipoprotein; LDL, low-density lipoprotein; HDL, high-
density lipoprotein; IDL, intermediate-density lipoprotein; VLDL, very-low-density lipoprotein.
https://doi.org/10.1371/journal.pmed.1003751.g005
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taken in young adulthood only, higher limb lean mass index was more weakly associated with
lower atherogenic trait levels, and these associations appeared to be driven by higher lean mass
held within legs; leg lean mass index was in turn more positively associated with creatinine
than was arm lean mass index. This is in strong contrast to cross-sectional associations of
higher fat mass index with atherogenic traits, which were highly consistent with prospective
associations in terms of the direction and magnitude of point estimates. Thus, if reflective of
causality, gaining muscle mass over time may be anticipated to confer greater cardiometabolic
benefits than simply having higher current or usual levels of muscle mass; but with benefits
likely of a lower magnitude than those anticipated for fat loss. Alternatively, the fragility of
results for lean mass indices, as compared with fat mass index, could be more indicative of bias
and residual confounding in estimates of lean mass than of robust causality.
Associations of muscle strengthening with atherogenic traits were highly dependent on the
grip measure used. Change in grip measured in absolute units (maximum grip) was positively
associated with creatinine but generally unassociated with atherogenic traits, with point esti-
mates close to null values of no difference. In contrast, change in grip measured in relative
units (as a function of body weight) was also positively associated with creatinine but generally
only weakly associated with atherogenic traits in directions assumed to indicate better health,
e.g., lower apolipoprotein B lipids, glycaemia, and inflammation. The magnitudes of these
Fig 6. Associations of change in fat mass index at different life stages with cardiometabolic traits at 25 y among Avon Longitudinal Study of Parents and Children
Generation 1 individuals. Estimates are beta coefficients and 95% CIs representing SD-unit differences in cardiometabolic traits at 25 y per SD-unit gain in total fat
mass index in childhood (based on standardised index at 13 y minus standardised index at 10 y), adolescence (based on standardised index at 18 y minus standardised
index at 13 y), and young adulthood (based on standardised index at 25 y minus standardised index at 18 y). Models adjusted for age, sex, ethnicity, maternal education,
initial fat mass index, and change in limb lean mass index; models of adolescence additionally adjusted for puberty timing, and models for young adulthood additionally
adjusted for puberty timing and smoking and alcohol at 18 y (N range: 1,532 to 2,804). Apo, apolipoprotein; LDL, low-density lipoprotein; HDL, high-density
lipoprotein; IDL, intermediate-density lipoprotein; VLDL, very-low-density lipoprotein.
https://doi.org/10.1371/journal.pmed.1003751.g006
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associations of change in relative grip were higher than those seen for change in arm lean mass
index but generally lower than those seen for change in fat mass index, particularly among
males, where evidence was strongest. Furthermore, associations of higher maximum and rela-
tive grip strength with atherogenic traits were even less evident when assessed cross-sectionally
in young adulthood, with point estimates close to null values. Considered alongside results on
lean and fat mass indices, this supports body muscle as less robustly associated with cardiome-
tabolic health in young adulthood than body fat, with a lower anticipated impact on CVD sus-
ceptibility from its modification. Resistance-based (muscle-building) physical activity is
supported by several randomised controlled trials (RCTs) among adults with or without meta-
bolic dysfunction as reducing blood pressure, but as having little to no effect on reducing glu-
cose or non-HDL lipids [51,52]. Such trials are typically small (N< 100), with short follow-up
(<1 y), but glycaemic and lipid benefits are seen in other RCTs of resistance- and aerobic-
based activities among adults with type 2 diabetes [53,54]. Any physical activity biomechani-
cally involves contracting some muscle, and habitual activity may mark contractile frequency.
Prospective observational evidence supports favourable associations of habitual activity with
cardiometabolic health [55,56], seen also among ALSPAC adolescents [57] at about half the
magnitude presently seen for body fat. Altogether, evidence seems to indicate that the regular
use of muscle matters more than the intentional building up of muscle for reducing CVD
susceptibility.
Whether associations of lean mass gain with susceptibility traits are truly sensitive to body
developmental stage is uncertain. Presently, associations of change in arm lean mass index
(the compartment associated with higher creatinine and taken to best reflect muscle) with car-
diometabolic traits were in directions assumed unfavourable to health for gains in childhood,
favourable for gains in adolescence, and null for gains in young adulthood. Adolescence is an
active period of growth and development following puberty [35], but how this may confer
exclusive benefits of muscle gain is unclear. Several RCTs of resistance-based activity among
children and adolescents support benefits for blood pressure, glycaemia, and lipids among
both age groups [58], and there is suggestion of larger benefits with greater maturity [34], pos-
sibly reflecting greater modifiability of muscle. In the present study, grip was not measured in
adolescence to enable comparisons, but associations seen for lean gain were distinct from
those seen for fat gain, which involved consistently unfavourable associations with traits across
sub-periods, with a tendency for larger effect sizes for more recent gains. Replication of associ-
ations in different study samples with triangulated approaches involving different sources of
bias [59] is needed.
Study limitations
This study is observational and effect estimates are prone to biases from unmeasured and
poorly measured confounders. Major sources of confounding of the relationship between
muscle and fat and cardiometabolic traits are expected to include subclinical disease and
behaviours like smoking, but both of these factors are expected to be less influential at younger
ages given their rarity or recency of onset. In addition to current exposure levels, our analyses
were based on changes in body muscle measures occurring early in life in relation to cardiome-
tabolic traits measured in young adulthood (age 25 y). These included an observation period
of young adulthood (age 18 to 25 y), which should be relevant to adulthood more broadly, but
results based on changes occurring over childhood and adolescence (periods of growth and
development with pronounced hormonal activity) may not represent the impact of changes
occurring later in life. Muscle mass and strength may plausibly be more influential for CVD
susceptibility at older ages, when CVDs commonly start to emerge; obtaining unbiased
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estimates of effect in middle to later adulthood is difficult, however, because of increased
potential for residual confounding (reverse causation). Other study designs such as MR may
prove useful here.
Muscle mass was estimated using DXA, which is more precise than bioimpedance but less
granular than MRI and less able to exclude ectopic fat stored within muscle. We examined cor-
relations among change in each limb lean mass compartment and total fat mass, which helps
identify compartments that are more susceptible to confounding by residual fat. Grip was not
measured in adolescence, preventing examination of change in grip across sub-periods. The
participants analysed were relatively lean and predominantly white European; this limits gen-
eralisability to other groups but reduces confounding by disease and ancestral population
structure. Sample sizes were modest; this is a tradeoff of detailed phenotyping and reduces pre-
cision. We applied metabolomics in a holistic manner; the large scope of analyses, particularly
given sex differences, prevented examination of the shape of associations. Changes in expo-
sures and outcomes are assumed to be linearly associated, i.e., negative change (loss) the
inverse of positive change (gain); this may not always hold. Examinations of non-linearity are
needed and would be aided by the prioritisation of cardiometabolic traits with triangulated
evidence of causality for CVD.
Conclusions
Our results suggest that muscle strengthening, as indicated by grip strength gain, is weakly
associated with lower atherogenic trait levels in young adulthood, particularly among males.
Such associations of gain in muscle mass with traits appear smaller and limited to gains occur-
ring in adolescence. Gaining body fat was more consistently associated with the same athero-
genic traits, in unfavourable directions and at larger magnitudes than seen for muscle mass or
strength, again particularly among males. Altogether, results suggest that body muscle is less
robustly associated with markers of CVD susceptibility than body fat and may therefore be a
lower-priority intervention target.
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and fat mass with all-cause mortality in older adults: the Cardiovascular Health Study. Nutr Metab Cardi-
ovasc Dis. 2016; 26(11):1039–47. https://doi.org/10.1016/j.numecd.2016.06.011 PMID: 27484755
19. Farmer RE, Mathur R, Schmidt AF, Bhaskaran K, Fatemifar G, Eastwood SV, et al. Associations
between measures of sarcopenic obesity and risk of cardiovascular disease and mortality: a cohort
study and Mendelian randomization analysis using the UK Biobank. J Am Heart Assoc. 2019; 8(13):
e011638. https://doi.org/10.1161/JAHA.118.011638 PMID: 31221000
20. Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of muscle mass (sarcope-
nia) and strength. Am J Med. 2006; 119(6):526.e9–17.
21. Lawman HG, Troiano RP, Perna FM, Wang C-Y, Fryar CD, Ogden CL. Associations of relative handgrip
strength and cardiovascular disease biomarkers in US adults, 2011–2012. Am J Prev Med. 2016; 50
(6):677–83. https://doi.org/10.1016/j.amepre.2015.10.022 PMID: 26689977
22. Li D, Guo G, Xia L, Yang X, Zhang B, Liu F, et al. Relative handgrip strength is inversely associated with
metabolic profile and metabolic disease in the general population in China. Frontiers Physiol. 2018;
9:59. https://doi.org/10.3389/fphys.2018.00059 PMID: 29459831
23. Lee W-J, Peng L-N, Chiou S-T, Chen L-K. Relative handgrip strength is a simple indicator of cardiome-
tabolic risk among middle-aged and older people: a nationwide population-based study in Taiwan.
PLoS ONE. 2016; 11(8):e0160876. https://doi.org/10.1371/journal.pone.0160876 PMID: 27559733
24. Byeon JY, Lee MK, Yu M-S, Kang MJ, Lee DH, Kim KC, et al. Lower relative handgrip strength is signifi-
cantly associated with a higher prevalence of the metabolic syndrome in adults. Metab Syndr Relat Dis-
ord. 2019; 17(5):280–8. https://doi.org/10.1089/met.2018.0111 PMID: 30945974
25. Chun S-W, Kim W, Choi KH. Comparison between grip strength and grip strength divided by body
weight in their relationship with metabolic syndrome and quality of life in the elderly. PLoS ONE. 2019;
14(9):e0222040. https://doi.org/10.1371/journal.pone.0222040 PMID: 31490975
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